Universal Ibogaine Inc.
IBOGF
$0.065
-$0.005-7.14%
| 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.08% | 1,326.80% | -- | 311.86% | 8.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.08% | 1,326.80% | -- | 311.86% | 8.51% |
| Cost of Revenue | 24.44% | 122.07% | 176.28% | 91.69% | 69.10% |
| Gross Profit | 28.23% | 220.65% | 210.32% | 568.82% | -62.49% |
| SG&A Expenses | 6.17% | -52.79% | -53.51% | -81.89% | -65.16% |
| Depreciation & Amortization | 11.05% | 17.67% | 23.90% | 7.15% | -5.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.34% | -8.57% | -0.27% | -52.64% | -47.66% |
| Operating Income | -3.39% | 76.91% | 79.90% | 97.26% | 65.78% |
| Income Before Tax | -76.87% | 72.02% | 75.80% | 93.38% | 61.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.87% | 72.02% | 75.80% | 93.38% | 61.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.87% | 72.02% | 75.80% | 93.38% | 61.22% |
| EBIT | -3.39% | 76.91% | 79.90% | 97.26% | 65.78% |
| EBITDA | -1.84% | 85.82% | 89.34% | 105.59% | 69.80% |
| EPS Basic | -15.79% | 70.97% | 75.76% | 93.13% | 61.22% |
| Normalized Basic EPS | 33.33% | 70.00% | 76.19% | 96.77% | 60.00% |
| EPS Diluted | -15.79% | 70.97% | 75.76% | 94.09% | 61.22% |
| Normalized Diluted EPS | 33.33% | 70.00% | 76.19% | 96.77% | 60.00% |
| Average Basic Shares Outstanding | 48.54% | 0.16% | 0.53% | 0.56% | 0.39% |
| Average Diluted Shares Outstanding | 48.54% | 0.16% | 0.53% | 0.56% | 0.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
